AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
NeoGenomics, Inc.
Video analysis: NEO
All videosNo video analysis for this stock yet. Request one from our team.
News: NEO
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and a string of open-market insider purchases.
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will parti
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.
NeoGenomics (NASDAQ:NEO) Sets New 12-Month High – Here’s What Happened
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $17.46 and last traded at $17.37, with a volume of 1679789 shares. The stock had previously closed at $16.79. Analyst Ratings Changes Several equities analysts have commented on the
NeoGenomics Inc (NEO) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 73/100
Valuation Assessment of NeoGenomics Inc (NEO)On August 26, 2026, NeoGenomics Inc (NEO) shares rose 3.5% today, closing at $17.37. The stock has experienced a no
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
